TRENTON, N.J.--(BUSINESS WIRE)--BioNJ's Second Annual Beyond Value Frameworks Workshop is taking place Thursday, December 7 at Amicus Therapeutics, Cranbury, NJ. Entitled "Continuing the Conversation...Seeking Solutions", this year's event will bring together Patients, industry, payers, academia and government to discuss and contribute to the development of new platforms that will provide Patients with access to the right medicines at the right time at affordable out-of-pocket costs. Click here for the full agenda.
"There is a lot of discussion about using value frameworks to reduce the cost of drugs and increase Patient access," said BioNJ President and CEO Debbie Hart. "However, unfortunately, such evaluations assume that on average, everyone will respond to all drugs in the same way, when in fact, the same treatment can have different benefits to different Patients. Moreover, value frameworks are used by insurance companies to steer Patients to the least-expensive products by imposing higher cost-sharing and more barriers to obtaining recommended treatments, even if the other drugs are not as effective or oftentimes, don't work.
"BioNJ's Beyond Value Frameworks Workshop is about bringing together all the stakeholders for an open conversation on this vital topic," added Hart. "Our roster of industry thought leaders will lead interactive, insightful discussions that will provide information, tools and strategies for understanding and dealing with value frameworks to ensure that Patient value shapes access."
Mark Alles, CEO, Celgene Corporation
John Crowley, Chairman of the Board & CEO, Amicus Therapeutics
Bob Feeney, Head, North America Government Affairs & Policy, Ipsen
Bob Gold, Clinical Behavioral Technologist & Founder, GoMo Health
Robert Goldberg, Ph.D., Vice President & Co-Founder, Center for Medicine in the Public Interest
Jennifer Hinkel, Partner at McGivney Global Advisors
Iya Khalil, Ph.D., Co-Founder & Chief Commercial Officer, GNS Healthcare
Steven Peskin, M.D., Executive Medical Director, Population Health, Horizon Blue Cross Blue Shield of New Jersey
Kevin Rigby, General Manager, Rigby Consulting
Sanjeev Wadhwa, Founder, President & CEO, Life Singularity
Burt Zwiegenhaft, Managing Partner, Upstream-Partners, LLC & Past President, National Association of Specialty Pharmacy
Designed for individuals responsible for pricing, policy, market access and reimbursement If you are responsible for pricing, policy, market access or reimbursement, the registration price for BioNJ Members and affiliated organizations is $195 and $295 for Future Members. Click here to register. (This event is closed to media.) For more information, visit www.BioNJ.org or call (609) 890-3185.
BioNJ is a network of 400 Member companies representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can't Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.